We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ligand Pharmaceuticals has reported results of two pivotal Phase III studies
of Targretin (bexarotene) capsules in front-line combination therapy with standard
chemotherapy to treat advanced non-small cell lung cancer (NSCLC).
Genta has released long-term follow-up results from the company's Phase III
trial of Genasense (oblimersen sodium) injection in patients with advanced malignant
melanoma.
Peregrine Pharmaceuticals has announced that a research article titled, "A
Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels
Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice,"
was published in the May 15 issue of Cancer Research.
Regeneron Pharmaceuticals and the sanofi-aventis Group have initiated a safety
and tolerability study of the vascular endothelial growth factor (VEGF) trap
in combination with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) in patients
with advanced solid malignancies.
Pharmacyclics has published interim data from a Phase I dose-escalation study
of Xcytrin (motexafin gadolinium) injection, the company's lead anticancer agent,
in combination with Taxotere (docetaxel) for the treatment of patients with
advanced refractory tumors.
Adherex Technologies has initiated a Phase Ib/II clinical trial of ADH-1 (Exherin(TM))
at the M.D. Anderson Cancer Center in Houston in advanced cancer patients who
express the tumor molecular target N-cadherin.
Depomed has announced results from its extended Phase II trial of Furosemide
GR, a controlled-release formulation of the leading diuretic furosemide, which
is used to treat edema in congestive heart failure (CHF) patients.
Bayer Pharmaceuticals and Onyx Pharmaceuticals have announced the opening of
a randomized, double-blind Phase III trial administering sorafenib (formerly
BAY 43-9006) in combination with the chemotherapeutic agents carboplatin and
paclitaxel in patients with advanced metastatic melanoma.